Skip to main content

Casirivimab / Imdevimab Dosage

Medically reviewed by Drugs.com. Last updated on Apr 8, 2024.

Applies to the following strengths: 1332 mg/11.1 mL-1332 mg/11.1 mL; 300 mg/2.5 mL-300 mg/2.5 mL; 1332 mg/11.1 mL-300 mg/2.5 mL; 300 mg/2.5 mL-1132 mg/11.1 mL; 600 mg-600 mg/10 mL

Usual Adult Dose for COVID-19

For investigational use only

At least 40 kg:


Comments:

Use: For the treatment of mild to moderate COVID-19 in patients with positive results of direct SARS-CoV-2 viral testing who are at high risk for progression to severe COVID-19, including hospitalization or death

Usual Adult Dose for Postexposure Prophylaxis

For investigational use only

At Least 40 kg:
Single Dose:


Repeat Dosing:

Comments:

Use: For the postexposure prophylaxis of COVID-19 in individuals who are at high risk for progression to severe COVID-19, including hospitalization or death, and are:

Usual Pediatric Dose for COVID-19

For investigational use only

12 years or older, weighing at least 40 kg:


Comments:

Use: For the treatment of mild to moderate COVID-19 in patients with positive results of direct SARS-CoV-2 viral testing who are at high risk for progression to severe COVID-19, including hospitalization or death

Usual Pediatric Dose for Postexposure Prophylaxis

For investigational use only

12 Years or Older, Weighing At Least 40 kg:
Single Dose:


Repeat Dosing:

Comments:

Use: For the postexposure prophylaxis of COVID-19 in individuals who are at high risk for progression to severe COVID-19, including hospitalization or death, and are:

Renal Dose Adjustments

Renal dysfunction: No adjustment recommended.

Liver Dose Adjustments

Data not available

Precautions

US BOXED WARNINGS:


CONTRAINDICATIONS:
Previous severe hypersensitivity reactions (including anaphylaxis) to either active component or to any of the ingredients

Safety and efficacy have not been established in patients younger than 18 years; this product (casirivimab and imdevimab) is not recommended for use in pediatric patients weighing less than 40 kg or those younger than 12 years.

Dialysis

Data not available

Other Comments

January 24, 2022: Due to the high frequency of the Omicron variant, this product is not currently authorized in any US region; therefore, this product may not be administered for treatment or postexposure prevention of COVID-19 under the EUA until further notice by the US FDA.

Administration advice:

ADMINISTRATION BY IV INFUSION:
ADMINISTRATION BY SUBCUTANEOUS INJECTION:

Storage requirements:

Reconstitution/preparation techniques:
PREPARATION FOR IV INFUSION:
PREPARATION FOR SUBCUTANEOUS INJECTION:

IV compatibility:

General:

Patient advice:

More about casirivimab / imdevimab

Patient resources

Other brands

REGEN-COV

Professional resources

Other brands

REGEN-COV

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.